quinoxalines has been researched along with zidovudine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I | 2 |
| Balzarini, J; Dunkler, A; Kleim, JP; Merigan, TC; Oette, D; Riess, G; Suarez, JR; Winkler, I; Winters, M | 1 |
| Aweeka, F; Hayashi, S; Jayesekera, D; Jayewardene, A; Shah, A; Thevanayagam, L | 1 |
| Aiello, F; Armaroli, S; Bergamini, A; Bolacchi, F; Bongiovanni, B; Caccia, S; Campiani, G; Capozzi, M; Coletta, M; Fabbrini, M; Garofalo, A; Greco, G; Guiso, G; Maga, G; Marini, S; Morelli, E; Nacci, V; Novellino, E; Ramunno, A; Spadari, S; Ventura, L | 1 |
2 trial(s) available for quinoxalines and zidovudine
| Article | Year |
|---|---|
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1999 |
Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Exanthema; Female; Gastrointestinal Diseases; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
3 other study(ies) available for quinoxalines and zidovudine
| Article | Year |
|---|---|
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.
Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Drug Resistance; HIV-1; Humans; Lamivudine; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
Topics: Animals; Anti-HIV Agents; Biological Availability; Cell Line; Didanosine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Models, Molecular; Pyridines; Quinoxalines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiourea; Zidovudine | 2001 |